Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention | Zendy

Vladimir Skljarevski | Zendy; Tina M. Oakes | Zendy; Qi Zhang | Zendy; Margaret B. Ferguson | Zendy; James M. Martinez | Zendy; Angelo Camporeale | Zendy; Kirk W. Johnson | Zendy; Qiu-Ling Shan | Zendy; Jeffrey Carter | Zendy; Aaron L. Schacht | Zendy; Peter J. Goadsby | Zendy; David W. Dodick | Zendy

AI Assistant Blog Pricing

Open Access

Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention

Author(s) -

Vladimir Skljarevski,

Tina M. Oakes,

Qi Zhang,

Margaret B. Ferguson,

James M. Martinez,

Angelo Camporeale,

Kirk W. Johnson,

Qiu-Ling Shan,

Jeffrey Carter,

Aaron L. Schacht,

Peter J. Goadsby,

David W. Dodick

Publication year - 2017

Publication title -

jama neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.298

H-Index - 231

eISSN - 2168-6157

pISSN - 2168-6149

DOI - 10.1001/jamaneurol.2017.3859

Subject(s) - migraine , placebo , medicine , calcitonin gene related peptide , chronic migraine , randomization , randomized controlled trial , population , neurology , anesthesia , physical therapy , psychiatry , pathology , alternative medicine , receptor , environmental health , neuropeptide

Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog